In vitro development of resistance to enrofloxacin, erythromycin, tylosin, tiamulin and oxytetracycline in Mycoplasma gallisepticum, Mycoplasma iowae and Mycoplasma synoviae.
The in vitro emergence of resistance to enrofloxacin, erythromycin, tylosin, tiamulin, and oxytetracycline in three avian Mycoplasma species, Mycoplasma gallisepticum, Mycoplasma synoviae and Mycoplasma iowae was studied. Mutants were selected stepwise and their MICs were determined after 10 passages in subinhibitory concentrations of antibiotic. High-level resistance to erythromycin and tylosin developed within 2-6 passages in the three Mycoplasma species. Resistance to enrofloxacin developed more gradually. No resistance to tiamulin or oxytetracycline could be evidenced in M. gallisepticum or M. synoviae after 10 passages whereas, resistant mutants were obtained with M. iowae. Cross-sensitivity tests performed on mutants demonstrated that mycoplasmas made resistant to tylosin were also resistant to erythromycin, whereas mutants made resistant to erythromycin were not always resistant to tylosin. Some M. iowae tiamulin-resistant mutants were also resistant to both macrolide antibiotics. Enrofloxacin and oxytetracycline did not induce any cross-resistance to the other antibiotics tested. These results show that Mycoplasma resistance to macrolides can be quickly selected in vitro, and thus, providing that similar results could be obtained under field conditions, that development of resistance to these antibiotics in vivo might also be a relatively frequent event.
Agence Française de Sécurité Sanitaire des Aliments, Laboratoire d'Etudes et de Recherches Avicoles et Porcines, Unité de Mycoplasmologie-Bactériologie, BP 53, 22440, Ploufragan, France. a.bouchardon@ploufragan.afssa.fr
A V
AV
Gautier-Bouchardon
A K
AK
Reinhardt
M
M
Kobisch
I
I
Kempf
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004224:Diterpenes / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D000077422:Enrofloxacin; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D009178:Mycoplasmataceae / Q000187:drug effects* / Q000235:genetics; D009180:Mycoplasmatales Infections / Q000188:drug therapy; D010118:Oxytetracycline / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology*; D015645:Tylosin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D004224:Diterpenes; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin; D004917:Erythromycin; C014224:tiamulin; D010118:Oxytetracycline; D015645:Tylosin